29709-35-1

Basic information

• Product Name: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE
• Synonyms: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE;2-(1H-pyrrol-1-yl)ethylamine;2-(1H-pyrrol-1-yl)ethanamine;2-(1H-pyrrol-1-yl)ethanamine(SALTDATA: FREE);2-(1H-pyrrol-1-yl)ethan-1-aMine;1H-Pyrrole-1-ethanaMine;2-(1-pyrrolyl)ethanamine;2-pyrrol-1-ylethanamine
• CAS NO: 29709-35-1
• Molecular Formula: C₆H₁₀N₂
• Molecular Weight: 110.16
• Mol File: 29709-35-1.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 60°/0.3mm
• Flash Point: 70.5°C
• Appearance: /
• Density: 1.02g/cm³
• Vapor Pressure: 0.477mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.53±0.10(Predicted)
• CAS DataBase Reference: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE(29709-35-1)
• EPA Substance Registry System: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE(29709-35-1)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 29709-35-1(Hazardous Substances Data)

Usage

Description

2-(1H-PYRROL-1-YL)-1-ETHANAMINE is an organic compound with the molecular formula C6H10N2. It is a heterocyclic amine derivative, characterized by the presence of a pyrrole ring and an ethanamine group. 2-(1H-PYRROL-1-YL)-1-ETHANAMINE serves as a versatile building block in the synthesis of various complex organic molecules and pharmaceuticals.

Uses

Used in Pharmaceutical Synthesis:
2-(1H-PYRROL-1-YL)-1-ETHANAMINE is used as a synthetic intermediate for the preparation of dihydropyrrolo[2′,1′:3,4]pyrazino[2,1-a]isoindolones. These complex molecules are synthesized by reacting 2-(1H-PYRROL-1-YL)-1-ETHANAMINE with 2-formylbenzoic acids or 2-acetylbenzoic acid through N-acyliminium cation aromatic cyclizations. The resulting products, such as those previously listed as CBR00085, have potential applications in the development of new drugs and therapeutic agents.
Used in Chemical Research:
In addition to its pharmaceutical applications, 2-(1H-PYRROL-1-YL)-1-ETHANAMINE is also utilized in chemical research as a starting material for the synthesis of various heterocyclic compounds. Its unique structure allows for further functionalization and modification, making it a valuable tool in the development of novel chemical entities with potential applications in various industries, including materials science, agrochemistry, and specialty chemicals.

InChI:InChI=1/C6H10N2/c7-3-6-8-4-1-2-5-8/h1-2,4-5H,3,6-7H2

Upstream product

• 86241-05-6 2-(1H-pyrrol-1-yl)acetonitrile 
• 89532-47-8 pyrrol-1-yl-acetic acid amide 
• 69309-33-7 1,4-bis-(dimethylamino)-1,3-butadiene 
• 107-15-3 ethylenediamine 
• 109-97-7 pyrrole 
• 870-24-6 2-chloroethanamine hydrochloride 
• 73627-16-4 N-[2-(1H-pyrrol-1-yl)ethyl]acetamide 
• 98019-88-6 3,4-Dibrom-butyraldehyd 
• 689-98-5 chloroethylamine 
• 7440-44-0 pyrographite 
• 696-59-3 cis,trans-2,5-dimethoxytetrahydrofuran 

Downstream Products

• 71257-37-9 3,4-dihydropyrrolo[1,2-a]-pyrazine 
• 73627-27-7 1-(3,4,5-Trimethoxyphenyl)-1,2,3,4-tetrahydropyrrolo<1,2-a>pyrazine 
• 127418-82-0 1-<2-(4'-nitrobenzoyl)aminoethyl>pyrrole 
• 478552-96-4 5,6,9,10,11,11a-hexahydro-8H-pyrido[1,2-a]pyrrolo[2,1-c]pyrazine 
• 136927-87-2 1-(2-(N-benzoylamino)ethyl)pyrrole 
• 945655-30-1 6-chloro-N-(2-pyrrol-1-yl-ethyl)nicotinamide 
• 924867-44-7 1-(6-chloro-3-pyridinyl)-3,4-dihydropyrrolo[1,2-a]pyrazine 
• 819814-73-8 6,8-dibromo-1-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazine 

Relevant articles and documents

Synthesis of Size-Tunable Hollow Polypyrrole Nanostructures and Their Assembly into Folate-Targeting and pH-Responsive Anticancer Drug-Delivery Agents

Chemotherapeutic drugs currently used in clinical settings have high toxicity, low specificity, and short half-lives. Herein, polypyrrole-based anticancer drug nanocapsules were prepared by tailoring the size of the nanoparticles with a template method, controlling drug release by means of an aromatic imine, increasing nanoparticle stability through PEGylation, and improving tumor-cell selectivity by folate mediation. The nanoparticles were characterized by TEM and dynamic light scattering. α-Folate receptor expression levelsof tumor cells and normal cells were investigated by western blot and quantitative polymerase chain reaction analyses. Flow cytometry and fluorescence imaging were used to verify the cell uptake of the different-sized nanoparticles. From the different-sized polypyrrole nanoparticles, the optimally functionalized nanoparticles of 180 nm hydrodynamic diameter were chosen and further usedfor in vitroandin vivotests. The nanoparticles showed excellent biocompatibility and the drug-loaded nanoparticles exhibited effective inhibition of tumor cell growth in vitro. Moreover, the drug-loaded nanoparticles showed substantially enhanced accumulation in tumor regions and effectively inhibitedin vivotumor growth. Furthermore, the nanoparticles showed reduced doxorubicin-induced toxicity andno significant side effects in normal organs of tumor-bearing mice, as measured by body-weight shifts and evaluationof drug distribution. Overall, the functionalized nanoparticles are promising nanocarriers for tumor-targeting drug delivery.

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

EIS INHIBITORS

Compounds and compositions are disclosed, which are useful as inhibitors of acetyltransferase Eis, a mediator of kanamycin resistance in Mycobacterium tuberculosis.